Oncotelic Therapeutics Inc Stock Price, News & Analysis

Oncotelic Therapeutics (OTCQB:OTLC) announced the grant of patent application no. 15/753,882 by the US Patent Office, focusing on a pharmaceutical composition to enhance anti-tumor effects using Vascular Disrupting Agents (VDAs) like combretastatin A4 phosphate. The CEO, Dr. Vuong Trieu, highlighted strengthening legacy assets including CA4P and Oxi4503 for challenging cancers, in conjunction with Pembrolizumab. The company is also targeting Parkinson's and erectile dysfunction with its acquired product AL-101, aiming for significant market needs amidst increasing patient diagnoses.

Oncotelic Therapeutics (OTLC) has appointed Dr. Seymour Fein as Chief Regulatory Officer, tasked with guiding the company’s registration trials globally. His extensive experience includes overseeing FDA approvals for over 20 drugs and managing the clinical consulting firm CNF Pharma. Following the completion of a joint venture for OT-101, a TGF-β antisense drug with demonstrated efficacy against hard-to-treat cancers, Dr. Fein aims to enhance Oncotelic's drug development efforts. The company focuses on improving treatment outcomes, especially in rare pediatric cancers.

Oncotelic Therapeutics (OTLC) has appointed Dr. Fatih Uckun as Chief Medical Officer, enhancing its leadership at a pivotal time for the company. Dr. Uckun, a veteran in oncology with over 30 years of experience, will oversee the execution of crucial registrational trials for OT-101, aimed at treating difficult cancers such as DIPG and pancreatic cancer. His extensive background includes significant achievements in immunotherapy research. The company recently completed a joint venture for OT-101, which has shown promise in previous clinical trials, including positive outcomes in treating COVID-19.

Oncotelic Therapeutics, Inc. (OTCQB:OTLC) announced its financial results for FY 2021, revealing a net loss of approximately $10.5 million, compared to a $10 million loss in FY 2020. The company reported no service revenue in FY 2021, a decline from $1.7 million in FY 2020. Research and development expenses decreased to $3.7 million, while general and administrative costs increased to $5.5 million. The company formed a joint venture with Dragon Overseas, expected to reduce future expenses, and anticipates significant operational changes in FY 2022, focusing on new drug developments and potential uplisting to a national stock exchange.

Oncotelic Therapeutics (OTCQB:OTLC) has formed a joint venture with Dragon Overseas Capital to develop TGF-β therapeutics, particularly focusing on the drug OT-101. This candidate targets pediatric brain cancer (DIPG) and shows promising safety and efficacy results. The JV will handle drug development costs, while Oncotelic anticipates financial benefits from a potential $50 million sale of a Rare Pediatric Disease voucher. Future clinical trials are planned, aiming for an IPO, bolstered by strong backing from Dragon Overseas, which is investing approximately $27.6 million for a majority stake.

Oncotelic Therapeutics (OTLC) has announced a Joint Venture (JV) with Dragon Overseas Capital Limited for the development of TGF-β therapeutics. This agreement will relieve Oncotelic of high drug development costs while allowing it to participate in the JV's financial upside. The JV will focus on OT-101, which has shown promise in clinical trials for conditions like DIPG and pancreatic cancer. Dragon Overseas will invest approximately $27.6 million for a 55% stake in the JV, while Oncotelic licenses OT-101 for a 45% ownership. The JV is headquartered in Hong Kong.

Oncotelic Therapeutics (OTCQB:OTLC) recently announced its plans to present studies on its TGF-β program at the AACR Annual Meeting 2022, highlighting the correlation between TGF-β expression and immune evasion in cancer and COVID-19.

The company's lead product, OT-101, has shown efficacy in over six clinical trials for solid tumors and a completed phase 2 trial against COVID-19. OT-101 is currently involved in a phase 1b trial combined with IL-2 and several upcoming trials with pembrolizumab.

Oncotelic Therapeutics, Inc. (OTCQB:OTLC) announced that Dr. Anthony E. Maida, Chief Clinical Officer, will present at the Evolution Summit in Los Angeles. Dr. Maida, an expert in immunotherapy, will discuss becoming truly patient-centric in healthcare. His career includes leading clinical research and raising over USD 200 million for biotech firms. Oncotelic focuses on developing TGF-β immunotherapies for late-stage cancers and has a promising drug candidate, OT-101. The company also acquired AL-101 for treating Parkinson's disease and erectile dysfunction.

Oncotelic Therapeutics (OTLC) announced Dr. Vuong Trieu's presentation at the MedInvest Pharmaceuticals and Biotechnology Investor Conference from March 28 - April 1, 2022. The company aims to reveal a Joint Venture with Golden Mountain Partners, which will focus on drug development and a new manufacturing facility. Oncotelic's lead drug, OT-101, has shown promising results in various clinical trials, including efficacy against solid tumors and COVID-19. The JV aims to secure funding for advancing Oncotelic's portfolio towards market approval.